Compare Exelixis Inc. Common Stock (EXEL) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs F5 Inc — how do they compare? Exelixis Inc. Common Stock trades at $60.1 (market cap $14.62B), while F5 Inc trades at $471.01 (market cap $26.14B). The key difference: F5 Inc is the larger of the two by market cap, and F5 Inc is more actively traded (503,146 versus 2,684,957). Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and F5 Inc for 38 Days on average.
| EXEL | FFIV | |
|---|---|---|
Market Cap | $14.62B | $26.14B |
Volume | 2,684,957 | 503,146 |
Sector | Health | Technology |
52-Week High | $59.13 | $469.79 |
52-Week Low | $34.54 | $223.99 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $13.95B | $24.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FFIV trades at $467.57, up 0.2% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.73 beating expectations of $4.00. Revenue grew to $3.09B in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security partnerships, reinforcing its market position.
The outlook remains positive given earnings momentum and strategic initiatives in AI security, though valuation multiples like P/E of 36.78 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $416.60 price target below current levels, indicating caution despite growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
